Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudarshan Pharma IndustriesBOM:543828 +1.24%74 Cyclically Adjusted PS Ratio is 0.48 as of Sep. 04, 2026, which is 26% above its 10-year median of 0.38. GuruFocus rates BOM:543828 with a GF Score™ of 74/100 and a GF Value™ of ₹6.92 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 1,269 Chemicals companies, Sudarshan Pharma Industries ranks better than 81.25% on this metric.
The historical rank and industry rank for Sudarshan Pharma Industries's Cyclically Adjusted PS Ratio or its related term are showing as below:
BOM:543828'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.32 Med: 0.38 Max: 0.48
Current: 0.48
During the past 10 years, Sudarshan Pharma Industries's highest Cyclically Adjusted PS Ratio was 0.48. The lowest was 0.32. And the median was 0.38.
BOM:543828's Cyclically Adjusted PS Ratio is ranked better than 81.25% of 1269
companies
in the Chemicals industry
Industry Median: 1.34
vs BOM:543828: 0.48
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Sudarshan Pharma Industries's adjusted revenue per share data of for the fiscal year that ended in Mar26 was ₹288.682. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹82.05 for the trailing ten years ended in Mar26.
Shiller PE for Stocks: The True Measure of Stock Valuation
Sudarshan Pharma Industries (BOM:543828) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Sudarshan Pharma Industries Cyclically Adjusted PS Ratio Related Terms
Sudarshan Pharma Industries Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudarshan Pharma Industries Cyclically Adjusted PS Ratio Chart
BOM:543828 vs DOW: Cyclically Adjusted PS Ratio Comparison
For the Chemicals subindustry, Sudarshan Pharma Industries's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudarshan Pharma Industries Cyclically Adjusted PS Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Sudarshan Pharma Industries's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Sudarshan Pharma Industries's Cyclically Adjusted PS Ratio falls into.
Sudarshan Pharma Industries Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.48 mean?
Sudarshan Pharma Industries (BOM:543828) has a Cyclically Adjusted PS Ratio of 0.48 as of Sep. 04, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sudarshan Pharma Industries and its competitors. This is 26% above median its historical median of 0.38. Over the past decade, Sudarshan Pharma Industries' Cyclically Adjusted PS Ratio has ranged from 0.32 to 0.48. According to the industry distribution chart, Sudarshan Pharma Industries ranks #238 out of 1269 companies in the Chemicals industry, placing it in the top 18.8%.
Is Sudarshan Pharma Industries' Cyclically Adjusted PS Ratio too high?
Sudarshan Pharma Industries' current Cyclically Adjusted PS Ratio of 0.48 is 26% above median its 10-year median of 0.38. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 0.48. The Chemicals industry median Cyclically Adjusted PS Ratio is 1.34. Sudarshan Pharma Industries' value of 0.48 is 64.2% below this industry median. Based on the distribution chart, Sudarshan Pharma Industries ranks #238 out of 1269 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Sudarshan Pharma Industries has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sudarshan Pharma Industries' Cyclically Adjusted PS Ratio compare to DOW?
According to the Chemicals industry distribution chart, Sudarshan Pharma Industries ranks #238 out of 1269 companies for Cyclically Adjusted PS Ratio. This places Sudarshan Pharma Industries in the top 19% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PS Ratio is 1.34. Sudarshan Pharma Industries' value of 0.48 is 64.2% below this benchmark. Historically, Sudarshan Pharma Industries' own Cyclically Adjusted PS Ratio has ranged from 0.32 to 0.48 over the past decade. While the company's 10-year median is 0.38 vs. the industry median of 1.34, Sudarshan Pharma Industries has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Chemicals company?
The median Cyclically Adjusted PS Ratio among Chemicals companies is 1.34, based on 1,269 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sudarshan Pharma Industries's current Cyclically Adjusted PS Ratio of 0.48 is 64.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sudarshan Pharma Industries and its competitors. For the Chemicals industry, the median Cyclically Adjusted PS Ratio is 1.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudarshan Pharma Industries's current Cyclically Adjusted PS Ratio is 0.48, which is 26% above median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudarshan Pharma Industries stock overvalued right now?
Based on GuruFocus' analysis, Sudarshan Pharma Industries (BOM:543828) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.92, compared to a current price of ₹39.42 — trading 469.7% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.48, which is 26% above median its 10-year median of 0.38 and 64.2% below the Chemicals industry median of 1.34. Sudarshan Pharma Industries' overall GF Score™ is 74/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Sudarshan Pharma Industries (BOM:543828), the current Cyclically Adjusted PS Ratio is 0.48 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sudarshan Pharma Industries (BOM:543828) Overvalued in 2026?
Based on GuruFocus' analysis, Sudarshan Pharma Industries stock appears to be overvalued.
The current stock price of ₹39.42 is trading 469.7% above its estimated GF Value™ of ₹6.92.
GuruFocus considers Sudarshan Pharma Industries to be Significantly Overvalued.
Key valuation signals for BOM:543828:
Cyclically Adjusted PS Ratio: 0.48 (26% above median its 10-year median of 0.38)
GF Value™: ₹6.92 vs. price of ₹39.42 (469.7% above fair value)
Industry Position: 64.2% below the Chemicals median (#238 of 1269)
No single metric tells the full story. See the BOM:543828 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sudarshan Pharma Industries Ltd operates in the pharmaceutical and chemical industries, focusing on specialty chemicals and intermediates used in pharmaceuticals, paints, food products, and adhesives. The Company has a presence domestically and internationally, participating regularly in trade fairs and exhibitions. The Company exports mainly to South East Asia, the Middle East, and North Africa. The Company also supplies generic pharmaceutical formulation as 'Make to order' for bulk supply to hospitals and related healthcare organisations. The company has one reportable segment of Specialty Chemicals.
74GF Score
Get the complete analysis for BOM:543828
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543828 has been successfully added to your 
